Overview

• The Lancet released a three-paper Series that synthesizes current evidence and urges coordinated global action to convert scientific gains into patient benefit.
• Phase 3 data show lecanemab and donanemab slow decline in early Alzheimer’s, with regulatory clearance in the US and EU alongside cautions over ARIA and modest benefit sizes.
• The Series says blood-based biomarkers are ready for routine memory assessments, setting up a shift toward earlier and simpler diagnosis.
• Implementation is uneven, as seen in Sweden where primary care is expanding blood testing while use of the drugs awaits national authorization.
• Authors warn that high prices, complex testing and monitoring, staffing shortfalls, and under-resourced services threaten equitable access, while urging population-wide prevention measures.